Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115266) titled 'RGS5 regulates PD-L1 through the c-Myc/STAT3 pathway, thereby inhibiting immune cell infiltration and leading to resistance to immunotherapy in gastric cancer' on Dec. 24, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Huzhou Center Hospital
Condition:
gastric cancer
Intervention:
RGS5 low-expression group:none
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: RGS5 low-expression group:50;RGS5 high-expression group:50;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?pr...